FDA approved KERENDIA (finerenone) as the first new treatment in 30 years for adults with chronic kidney disease associated ...

Vera Therapeutics, Inc. ( VERA) reported that in the pivotal ORIGIN 3 trial of TRUTAKNA (atacicept-vymj), an FDA-approved dual BAFF and APRIL inhibitor, it stabilised kidney function and prevented ...

Note: This article is written based on publicly available information and market data as of September 15, 2026.IntroductionThe TV commercials for "Sedes" when you have pain, or the vitamin supplement ...

GSK will acquire a Chimagen trispecific T cell engager for multiple myeloma in a deal worth up to $750M. Here's what it means ...

The U.S. Web Design System is intended to help the federal government build accessible and mobile-friendly websites.

Sustainability and operational resilience are converging into competitive advantages. AI achieves high-90% reliability with ...

AI in manufacturing is moving beyond experimentation as Autodesk advances AI-assisted workflows across Fusion, Inventor, Vault, and its platform.

GSK is acquiring global rights to a T cell engager that Chimagen Biosciences developed to hit three targets. GSK believes this tri-specific approach could offer advantages over currently available ...

Shares rose after strong clinical data strengthened the case for its $10.6 billion Nuvalent acquisition and broader push to rebuild oncology around lung cancer.

Zidesamtinib (Jideytro) demonstrated a high objective response rate (ORR) in patients with previously untreated ROS1-positive ...

GSK plc is moving further into antibody-drug conjugates, taking ex-China rights to Hutchmed Ltd.’s HMPL-A830 in a deal worth up to $1.295 billion, plus royalties. Of that, GSK is paying $110 million ...